Castle Biosciences (CSTL) to Release Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is expected to be releasing its earnings data after the market closes on Thursday, February 27th. Analysts expect Castle Biosciences to post earnings of ($0.04) per share and revenue of $83.89 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Castle Biosciences Price Performance

NASDAQ:CSTL opened at $25.09 on Wednesday. The stock has a market cap of $702.70 million, a P/E ratio of 125.46 and a beta of 0.91. Castle Biosciences has a one year low of $16.97 and a one year high of $35.84. The company has a fifty day moving average price of $27.40 and a 200 day moving average price of $29.24. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CSTL shares. KeyCorp upped their target price on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Scotiabank lifted their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 6th. Lake Street Capital lifted their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, Stephens reaffirmed an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a research note on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $40.29.

Insiders Place Their Bets

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 986 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.03, for a total value of $27,637.58. Following the transaction, the insider now owns 80,818 shares in the company, valued at $2,265,328.54. The trade was a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,771 shares of company stock valued at $886,112. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.